OraSure Technologies (OSUR) Expected to Announce Quarterly Earnings on Monday

OraSure Technologies (NASDAQ:OSUR) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect OraSure Technologies to announce earnings of ($0.18) per share and revenue of $31.00 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

OraSure Technologies Trading Up 2.1%

OSUR stock opened at $3.44 on Friday. The firm has a fifty day moving average price of $3.73 and a two-hundred day moving average price of $3.53. OraSure Technologies has a 1-year low of $2.08 and a 1-year high of $4.58.

Analyst Upgrades and Downgrades

OSUR has been the topic of several analyst reports. Craig Hallum upgraded shares of OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OraSure Technologies in a report on Tuesday, September 1st. Zacks Research upgraded shares of OraSure Technologies to a “hold” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.